OR WAIT null SECS
Kayentis has announced it is forging ahead on five new eCOA service projects with Emerging BioPharma companies. The projects Kayentis is collaborating on involve phase II and III clinical studies in therapeutic areas addressing unmet needs in areas like oncology, immune disorders, and rare diseases. In response to COVID-19, Kayentis has implemented a dedicated contingency plan for sites and patients to keep trials running.
For more information, click here.